Parents of ADHD Children
Clinical trials - New York area
Tue Nov 5, 2013 11:51 am (PST) . Posted by: “Harold Robert Meyer” haroldrmeyer *Title:* Neurobiological Basis of Response to Guanfacine Extended Release
in Children and Adolescents with ADHD: an fMRI Study of Brain Activation
Pre and Post Treatment
*Location: * Icahn School of Medicine at Mount Sinai, New York, NY
*Sponsor:* Shire Pharmaceuticals Inc.
Dr. Jeffrey Newcorn and his team at the Clinical Trials Program are
evaluating brain activation in response to Guanfacine, a medication used in
the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Please call if your child is between 8-15 years of age and experiences
symptoms of ADHD like being easily distracted, making careless mistakes,
being forgetful in daily activities, having difficulty paying attention,
and difficulty organizing.
Your child will receive at no cost: a comprehensive psychiatric and
physical screening to determine whether he or she has ADHD and is healthy
enough to be treated with medication; pre-and post-treatment fMRI scanning;
weekly visits with our physicians; up to 2 months of medication (either
during the trial or, if assigned to placebo, after 6 to 8 weeks of
participation); referral for on-going care with progress report of
The study lasts up to 9 weeks, but you may choose to see our doctors at no
cost for up to 2 additional months while your child is stabilized on the
medication that works best for him or her.
Reimbursement is available to participants and their parents.
If we do not have a research study that is right for you at this time, we
can refer you with other options and/or contact you for future studies.
Mount Sinai is located on the Upper East Side of Manhattan.
*Contact: *Beth Krone, Ph.D.
Top 5 This Month
ADDitude's most popular articles
ADDitude Special Reports
|More ADDitude Special Reports|
Important! User-Generated Content
The opinions expressed on ADDConnect are solely those of the user, who may or may not have medical training. These opinions do not represent the opinions of ADDConnect or ADDitude magazine. For more information, see our terms and conditions.